Science, Leiden Academic Centre for Drug Research (LACDR)

Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process.

Sebastian Pomplun manages to reach proteins with drugs even where this was thought impossible. That is why he and his research group have been allowed to join Oncode Institute. With nine others, he had been selected from 72 applicants to contribute to Oncode Institute's mission: to accelerate breakthroughs…

Due to the great influx of PhD candidates, we had the pleasure to organize a 2nd PhD Introductory Course on Drug research this year. From November 4- 6, we welcomed 30 participants for this 3-days event, which took place at Castle Oud Poelgeest.

On 14 April, the National Growth Fund awarded million euros in grants to two consortia in which Leiden's science faculty is involved. Pharma-NL will receive 80 million euros and Oncode-PACT 325 million euros. Pharma-NL wants to make medicines available to the patient faster and more sustainably. Oncode-PACT…

Cancer is still one of the most common diseases in the world. What exactly is cancer and will we one day be able to cure everyone? In a video from the Universiteit van Nederland Noel de Miranda (Tumour Immunology, LUMC) tells you about his research on new treatments.

Willem Jespers started his position as Assistant Professor in the group of Prof. G.J.P. van Westen on June 1st, a short introduction below:

There are more molecules that could conceivably be candidate drugs than there are stars in the universe. How can we ever efficiently identify those molecules? Professor of AI and Medicinal Chemistry, Gerard van Westen: ‘I’m going to use artificial intelligence as the co-pilot to make an automated search.’…

Biological chemist Nathaniel Martin and his team received an NWO grant to examine how blocking a specific enzyme in our body, NNMT, could be helpful in the treatment of some cancers. Trials with mice have been promising, and together with the Netherlands Cancer Institute, Martin wants to take the next…

A cancer pill, preferably without severe side effects, is something we’d all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves are contributing to new cancer treatments.

To inhibit proteins that contribute to the growth of aggressive cancer cells, that’s the plan of Professor Bob van de Water and his team. They will receive over 700,000 euros from the KWF Dutch Cancer Society for their research. Researcher Maaike Vreeswijk and pathologist Danielle Cohen are affiliated…

How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…

'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…

We already know a lot about genetics and the risk of breast cancer. But much still needs to be done in breast cancer genetics to improve the prognosis and make sure women at high risk aren’t missed. This is what Professor by Special Appointment Marjanka Schmidt will say in her inaugural lecture on 4…

When internist Christian Blank made his very first discovery, his field of immunotherapy was the underdog of cancer research. Now, over 20 years later, Blank has been appointed Professor By Special Appointment of Internal Medicine for his clinical research into immunotherapy and will give his inaugural…

A breakthrough from the PhD research of medical chemist Elmer Maurits may help patients with autoimmune diseases and blood cancer in the future. But bringing a discovery from the lab to the clinic is not so easily done. Thanks to NWO's Venture Challenge, Maurits and his team will receive ten weeks of…

Leiden University Medical Center (LUMC) has spent the past five years coordinating an international study of genetic mutations and breast cancer risks. The results will make it easier to determine which genes increase the risk of breast cancer and to what extent. The researchers published their results…

Leiden researchers have developed a groundbreaking model to advance cancer immunotherapy. Using a 3D printer, they create mini-tumors within an environment that closely mimics human tissue. They have also developed a method to monitor real-time interactions of these mini-tumours with immune cells during…

Oncode Investigator Mario van der Stelt and his colleagues have discovered a new potential drug that suppresses chemotherapy induced neuropathic pain.

Through its Demonstrator Projects, the Dutch Oncode Accelerator consortium provides grants for preclinical cancer therapy development. The first call for these projects is open until September 2025.

One discovered that arteriosclerosis resembles an autoimmune disease, while the other developed a system to aid in the search for new medications. For these achievements, Marie Depuydt and Jurren de Groot were awarded the Krijn Rietveld Memorial Innovation Award on the evening of Tuesday 4 June.

Developing new drugs is a difficult process. With the aid of artificial intelligence, Pharmaceutical scientist Xuhan Liu has developed methods that can help make drug design cheaper and faster. PhD defence on 15 February.

Researchers at the Universities of Amsterdam (Uva) and Leiden together with the Netherlands Cancer Institute and Oncode Institute have received a €10,6 million ERC Synergy Grant to develop innovative therapeutic approaches to target glioblastoma. This is a deadly primary brain tumour for which no curing…

Research

Using mathematics to help children with bone cancer. It sounds a little strange, but for statistician Marta Fiocco, it's just her job. She gets a substantial grant from KiKa for it. With that money, she is going to study the effect of chemotherapy adjustments.

On 11 November Professor of Gastroenterology and Hepatology, Monique van Leerdam will deliver her inaugural lecture entitled, ‘Aiming for Prevention’. Van Leerdam, who specialises in hereditary tumours, was appointed professor in July 2020. In her inaugural lecture she will discuss the importance of…

Patients with incurable cancer want their oncologist to be clear but to show empathy too. They find hard and vague communication harmful. These are the results of a study by psychologists from Leiden that has been published in the American journal Cancer.

Researchers from the Leiden University Medical Center (LUMC) have developed an AI model that accurately predicts the risk of endometrial cancer recurrence.

Researchers at the Leiden Institute of Advanced Computer Science (LIACS) are collaborating on the development of a conversation tool for patients with breast, prostate and skin cancer. The aim is to create a conversation tool that can support cancer patients in their care and help them make decisions.…

His article on ‘the War on Drugs’ in Colombia and the Philippines has been in the top five most downloaded articles of Oxford University Press for some time. Now, Assistant Professor Santino Regilme is to receive a NIAS grant to map out the global war on drugs.

Nerve pain is one of the most common side effects of chemotherapy. It is therefore one of the biggest reasons for cancer patients to stop treatment early. Darcy Reynolds worked on new drug candidates against this pain during her bachelor's thesis. She developed a new series of molecules that increase…

Psychedelic drugs like magic mushrooms and LSD are embraced by some and seen as lethal by others. Cognitive psychologist Michiel van Elk delved into the world of psychedelic drugs and wrote a surprisingly sober book about them. ‘Without first-hand experience my story wouldn’t be complete.’